Market Overview

Switching to CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) - Cas Systems from Uncultivated Microbes -


The "Switching
to CRISPR - Cas Systems from Uncultivated Microbes"
report has
been added to's offering.

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)
technology is currently the biggest discovery in life science. As a
precise gene editing tool, it has been widely used in many areas with a
great potential to treat human diseases. While some CRISPR-based
therapeutic studies are moving to clinical trials, CRISPR's therapeutic
promise was brought into question when some issues were found that could
become major obstacles in moving the great genome editing tools to the

While many groups are actively resolving these obstacles, the
significant challenges to minimize the immunological risks and avoid
potential tumorgenicity have received more attention as big concerns for
CRISPR-Cas therapeutics advancing toward the clinic.

We believe it is timely to summarize and analyze the emerging
immunological risk and potential tumorgenicity with the CRISPR-Cas
systems, to predict how this exciting genome editing market will affect
other related segments of the entire life science market in the next few
years. We also hope our opinion could serve as a ""crowd crystal"" on
those discussions in response to the issues, and bring a better market
environment for the technology to be sharpened and advanced into
clinical applications.

The Report Includes:

  • Detailed understanding of the two major types of adaptive immunity to
    Cas9 proteins, i.e. humoral immunity and cell-mediated immunity
  • Comparison of in vivo and ex vivo CRISPR-Cas9 therapy and discussion
    about clinical safety and probability to enter human clinical trials
  • Coverage of technical areas such as protein engineering and
    metagenomic analysis as driving forces to new CRISPR-Cas system
  • A look into the oncogenic risks by CRISPR-Cas9 genome editing and
    studies on the development and implementation of genetic systems
    designed to toggle tumor suppressor genes off and back-on again

Key Topics Covered:

Chapter 1 CRISPR Cas Genome Editing: Therapeutic or Thwarted by
Preexisting Human Immu

  • Immunogenicity Risk
  • Potential Solutions to Overcome Preexisting Immunity to Cas Proteins
    in Humans
  • Oncogenicity Risk
  • Potential Solutions to Overcome Oncogenicity Risk
  • What Could Happen Next?
  • Scientific Community
  • Investors
  • Regulatory Societies
  • What to Expect in the Market?

Chapter 2 A Note from the Editor

Chapter 3 Analyst's Credentials

For more information about this report visit

View Comments and Join the Discussion!